StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38−0.07 (-4.83%)

Close on Nov 17, 2026Market cap $192.56MP/E –Yield –

Inhibikase Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Inhibikase Therapeutics's total assets was $163.59M at Jun 30, 2026. For fiscal 2025 it was $181.20M, up 83.8% from the year before. The highest annual figure on record is $181.20M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$181.20M+83.8%
FY2024Dec 31, 2024$98.60M+579.7%
FY2023Dec 31, 2023$14.51M-41.8%
FY2022Dec 31, 2022$24.94M-41.3%
FY2021Dec 31, 2021$42.47M+187.3%
FY2020Dec 31, 2020$14.78M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$163.59M+84.1%
Q1 FY2026Mar 31, 2026$173.33M+83.8%
Q4 FY2025Dec 31, 2025$181.20M+83.8%
Q3 FY2025Sep 30, 2025$79.59M+1718.5%
Q2 FY2025Jun 30, 2025$88.85M+906.6%
Q1 FY2025Mar 31, 2025$94.28M+751.8%
Q4 FY2024Dec 31, 2024$98.60M+579.7%
Q3 FY2024Sep 30, 2024$4.38M-75.5%
Q2 FY2024Jun 30, 2024$8.83M-60.5%
Q1 FY2024Mar 31, 2024$11.07M-60.7%
Q4 FY2023Dec 31, 2023$14.51M-41.8%
Q3 FY2023Sep 30, 2023$17.88M-37.4%
Q2 FY2023Jun 30, 2023$22.35M-34.3%
Q1 FY2023Mar 31, 2023$28.16M-26.6%
Q4 FY2022Dec 31, 2022$24.94M-41.3%
Q3 FY2022Sep 30, 2022$28.58M-41.9%
Q2 FY2022Jun 30, 2022$33.99M+186.3%
Q1 FY2022Mar 31, 2022$38.39M+159.7%
Q4 FY2021Dec 31, 2021$42.47M–
Q2 FY2021Jun 30, 2021$49.22M–
Q1 FY2021Mar 31, 2021$11.87M–
Q4 FY2020Dec 31, 2020$14.78M–

More Inhibikase Therapeutics figures

See a number that looks wrong?